169 results on '"Morillas, Rosa M"'
Search Results
2. Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
3. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
4. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
5. TOP-241-YI Longitudinal changes in liver stiffness measurements in a population-based screening cohort of 5, 517 participants
6. THU-154-YI Diabetes mellitus (DM) is associated with worse outcomes in patients with primary biliary cholangitis (PBC) regardless of the presence of liver steatosis: results from the ColHai registry
7. WED-107 Administration of xyloglucan alone or in combination with norfloxacin improves intestinal barrier homeostasis in cirrhotic rats with ascites
8. Factores que influyen en la curación de la hepatitis C en la era de los antivirales de acción directa
9. Systematic review of the role of calprotectin in cirrhosis
10. High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study
11. HEPACONTROL. A program that reduces early readmissions, mortality at 60 days, and healthcare costs in decompensated cirrhosis
12. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
13. Early hospital readmission in decompensated cirrhosis: Incidence, impact on mortality, and predictive factors
14. Systematic review of the role of calprotectin in cirrhosis.
15. Real-life effectiveness of voxilaprevir/sofosbuvir/velpatasvir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
16. Impact of the metabolic profile on the response to ursodeoxycholic acid in patients with primary biliary cholangitis: results of the ColHai registry
17. Predictive models of treatment benefit in patients with autoimmune hepatitis and decompensated cirrhosis at diagnosis
18. Impact of obesity on transient elastography accuracy among patients with non-alcoholic fatty liver disease
19. Porto sinusoidal vascular liver disorder: natural history and long-term outcome
20. Further decompensation as a new prognostic stage in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements
21. Long-term prospective follow-up of a primary biliary cholangitis (PBC) multicenter cohort treated with Obeticholic Acid (OCA). Interaction effect of triple therapy with fibrates
22. Risk of decompensated cirrhosis in patients with primary biliary cholangitis under first, second and third-line therapies
23. Variation in the presentation pattern of primary biliary cholangitis (PBC) in Spain according to the diagnostic period: data from the Spanish registry of cholestatic and autoimmune liver diseases (COLHAI)
24. HCV micro-elimination strategy in a tertiary hospital: identification of lost cases and linkage to care
25. Incidence, risk factors and clinical outcomes of multidrug-resistant microorganism infections among patients admitted for decompensated cirrhosis: A prospective study
26. Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients
27. Incidence, risk factors and clinical outcomes of multidrug-resistant microorganism infections among patients admitted for decompensated cirrhosis: A prospective study
28. Should we seek complete liver tests normalization in primary biliary cholangitis? Data from ColHai registry
29. The metabolic dysfunction-associated fatty liver disease definition, regardless of its clinical subclassification, identifies patients at high risk for liver disease progression
30. Fecal microbiota trasplant using endoscopic-placement hydrogel reduces liver fibrosis with no changes in steatosis in a rat model of steatohepatitis with fibrosis
31. Metabolic dysfunction-associated fatty liver disease increases cardiovascular risk regardless of classical risk factors
32. Worsening of low-grade systemic inflammation heralds decompensation in patients with compensated cirrhosis
33. LiverScreen project:study protocol for screening for liver fibrosis in the general population in European countries
34. Population screening for liver fibrosis:Toward early diagnosis and intervention for chronic liver diseases
35. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration.
36. Additional file 3 of LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
37. Additional file 1 of LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
38. Additional file 2 of LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
39. Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
40. Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities
41. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis
42. Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease
43. Hepatitis autoinmune
44. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study
45. Serum Concentrations of Insulin-Like Growth Factor-I (IGF-I) as a Marker of Liver Fibrosis in Patients With Chronic Hepatitis C
46. THU-216 - Real-life effectiveness of voxilaprevir/sofosbuvir/velpatasvir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
47. THU-192 - HCV micro-elimination strategy in a tertiary hospital: identification of lost cases and linkage to care
48. SAT-468 - Impact of obesity on transient elastography accuracy among patients with non-alcoholic fatty liver disease
49. WED-290 - Predictive models of treatment benefit in patients with autoimmune hepatitis and decompensated cirrhosis at diagnosis
50. WED-300 - Variation in the presentation pattern of primary biliary cholangitis (PBC) in Spain according to the diagnostic period: data from the Spanish registry of cholestatic and autoimmune liver diseases (COLHAI)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.